The National Institutes Of Health Awarded A Contract To Cellectis Bioresearch Inc.

Cellectis bioresearch Inc. has been awarded a contract to provide services to the National Institutes of Health (NIH) and certain other government agencies

Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (Alternext: ALCLS), announces that it has been awarded a contract to provide services to the National Institutes of Health (NIH) and certain other government agencies.

This multiple award, indefinite delivery/indefinite quantity (IDIQ) contract, has a maximum order limit of $9,509,000 over a period of five years. Under the terms of the contract, the scope of work includes generation of induced pluripotent stem (iPS) cell lines of clinical grade and differentiation of iPS cells toward specific tissue cell type of clinical grade.

This major contract confirms the relevance of Cellectis’s investment since 2010 in license agreements for Professor Yamanaka’s iPS patents. Furthermore Professor Shinya Yamanaka has been awarded the 2012 Nobel Prize in Medicine.

“This contract won through a NIH call for tenders is the largest ever secured by Cellectis bioresearch Inc. It dedicates our company as a leading competitor and an expert in the field in the United States” said Marc Le Bozec, CEO of Cellectis bioresearch.

André Choulika, CEO of Cellectis declared: "this contract award granted by the most prestigious US research organization the NIH is a great recognition of our Science and confirms that Cellectis is one of the major players at developing stem cell technologies in both in vitro research applications and regenerative medicine.”